You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBarbital
Accession NumberDB01483
TypeSmall Molecule
GroupsIllicit
DescriptionA long-acting barbiturate that depresses most metabolic processes at high doses. It is used as a hypnotic and sedative and may induce dependence. Barbital is also used in veterinary practice for central nervous system depression. Barbital is a schedule IV controlled drug.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5WZ53ENE2P
CAS number57-44-3
WeightAverage: 184.1925
Monoisotopic: 184.08479226
Chemical FormulaC8H12N2O3
InChI KeyFTOAOBMCPZCFFF-UHFFFAOYSA-N
InChI
InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13)
IUPAC Name
5,5-diethyl-1,3-diazinane-2,4,6-trione
SMILES
CCC1(CC)C(=O)NC(=O)NC1=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinyes
potentiator
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinyes
potentiator
HumanP34903 details
Gamma-aminobutyric acid receptor subunit alpha-4Proteinyes
potentiator
HumanP48169 details
Gamma-aminobutyric acid receptor subunit alpha-5Proteinyes
potentiator
HumanP31644 details
Gamma-aminobutyric acid receptor subunit alpha-6Proteinyes
potentiator
HumanQ16445 details
Neuronal acetylcholine receptor subunit alpha-4Proteinunknown
antagonist
HumanP43681 details
Neuronal acetylcholine receptor subunit alpha-7Proteinunknown
antagonist
HumanP36544 details
Glutamate receptor 2Proteinunknown
antagonist
HumanP42262 details
Glutamate receptor ionotropic, kainate 2Proteinunknown
antagonist
HumanQ13002 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Barbital is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Barbital is combined with 7-Nitroindazole.Experimental
AcebutololBarbital may increase the hypotensive activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Barbital.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Barbital is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Barbital is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Barbital.Approved
AcetazolamideBarbital may increase the hypotensive activities of Acetazolamide.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Barbital is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Barbital is combined with Agomelatine.Approved, Investigational
AldesleukinBarbital may increase the hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Barbital is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Barbital.Approved, Illicit
AliskirenBarbital may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Barbital is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Barbital.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Barbital.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Barbital.Experimental
AmifostineBarbital may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideBarbital may increase the hypotensive activities of Amiloride.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Barbital.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Barbital.Approved
AmiodaroneBarbital may increase the hypotensive activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Barbital is combined with Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Barbital.Approved
AmlodipineBarbital may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Barbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Barbital is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Barbital is combined with Amperozide.Experimental
Amphotericin BBarbital may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmrinoneThe metabolism of Amrinone can be increased when combined with Barbital.Approved
Amyl NitriteBarbital may increase the hypotensive activities of Amyl Nitrite.Approved
Aop200704The serum concentration of Aop200704 can be decreased when it is combined with Barbital.Investigational
ApomorphineBarbital may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineBarbital may increase the hypotensive activities of Apraclonidine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Barbital.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Barbital.Approved
Arsenic trioxideBarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Barbital is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Barbital is combined with Asenapine.Approved
AtenololBarbital may increase the hypotensive activities of Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Barbital is combined with Azaperone.Vet Approved
AzelastineBarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Barbital is combined with Azelastine.Approved
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Barbital.Approved
Azilsartan medoxomilBarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved
AzimilideThe metabolism of Azimilide can be increased when combined with Barbital.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Barbital is combined with Baclofen.Approved
BarnidipineThe metabolism of Barnidipine can be increased when combined with Barbital.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Barbital.Experimental
BenazeprilBarbital may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideBarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be increased when combined with Barbital.Approved
BenperidolThe risk or severity of adverse effects can be increased when Barbital is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Barbital.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Barbital is combined with Benzyl alcohol.Approved
BepridilThe metabolism of Bepridil can be increased when combined with Barbital.Approved, Withdrawn
BetaxololBarbital may increase the hypotensive activities of Betaxolol.Approved
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Barbital.Approved
BisoprololBarbital may increase the hypotensive activities of Bisoprolol.Approved
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Barbital.Approved
BortezomibBarbital may increase the hypotensive activities of Bortezomib.Approved, Investigational
BretyliumBarbital may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Barbital is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Barbital is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved
BromazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Bromazepam.Approved, Illicit
BromocriptineBarbital may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Barbital is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Barbital is combined with Brotizolam.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Barbital.Investigational
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Barbital.Experimental, Investigational
BumetanideBarbital may increase the hypotensive activities of Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Barbital.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Barbital.Approved
BuprenorphineBarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Barbital.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Barbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Barbital is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Barbital is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Barbital.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Barbital.Approved, Illicit, Vet Approved
CaiThe metabolism of Cai can be increased when combined with Barbital.Investigational
CanagliflozinBarbital may increase the hypotensive activities of Canagliflozin.Approved
CandesartanBarbital may increase the hypotensive activities of Candesartan.Approved
CaptoprilBarbital may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Barbital.Approved, Investigational
CarbetocinBarbital may increase the hypotensive activities of Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Barbital is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Barbital is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Barbital is combined with Carisoprodol.Approved
CarteololBarbital may increase the hypotensive activities of Carteolol.Approved
CarvedilolBarbital may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Barbital.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Barbital is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Barbital is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Barbital can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Barbital.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Barbital.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Barbital.Approved
ChlorothiazideBarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Barbital.Withdrawn
ChlorphenamineThe risk or severity of adverse effects can be increased when Barbital is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Barbital.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Barbital.Approved, Withdrawn
ChlorthalidoneBarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Barbital is combined with Chlorzoxazone.Approved
CilazaprilBarbital may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Barbital.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Barbital.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Barbital.Approved
CitalopramThe risk or severity of adverse effects can be increased when Barbital is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Barbital is combined with Clemastine.Approved
ClevidipineBarbital may increase the hypotensive activities of Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Barbital is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Barbital is combined with Clobazam.Approved, Illicit
ClofarabineBarbital may increase the hypotensive activities of Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Barbital is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Clomipramine can be increased when combined with Barbital.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Barbital is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Barbital.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Barbital.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Barbital.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Barbital.Approved, Illicit
ConivaptanBarbital may increase the hypotensive activities of Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe therapeutic efficacy of Conjugated Equine Estrogens can be decreased when used in combination with Barbital.Approved
CyclizineThe risk or severity of adverse effects can be increased when Barbital is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Barbital.Approved
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Barbital.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Barbital is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Barbital is combined with Dantrolene.Approved
DapagliflozinBarbital may increase the hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Barbital.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Barbital is combined with Dapoxetine.Investigational
DarodipineThe metabolism of Darodipine can be increased when combined with Barbital.Experimental
deramciclaneThe risk or severity of adverse effects can be increased when Barbital is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Barbital.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Barbital.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Barbital is combined with Desloratadine.Approved, Investigational
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Barbital.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Barbital is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Barbital is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Barbital is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Barbital.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Barbital is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Barbital.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Barbital.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Barbital.Approved, Illicit, Vet Approved
DiclofenamideBarbital may increase the hypotensive activities of Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Barbital.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Barbital.Approved
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Barbital.Approved
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Barbital.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Barbital is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Barbital is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Barbital.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Barbital is combined with Dihydromorphine.Experimental, Illicit
DiltiazemBarbital may increase the hypotensive activities of Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Barbital is combined with Dimenhydrinate.Approved
DinutuximabBarbital may increase the hypotensive activities of Dinutuximab.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Barbital.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Barbital.Approved, Illicit
DipyridamoleBarbital may increase the hypotensive activities of Dipyridamole.Approved
DoramectinThe risk or severity of adverse effects can be increased when Barbital is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Barbital.Approved
DotarizineThe metabolism of Dotarizine can be increased when combined with Barbital.Investigational
DoxazosinBarbital may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be increased when combined with Barbital.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Barbital.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Barbital is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Barbital.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Barbital is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Barbital is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Barbital.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Barbital.Approved
EcgonineThe risk or severity of adverse effects can be increased when Barbital is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Barbital is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Barbital is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Barbital is combined with Efavirenz.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be increased when combined with Barbital.Approved
EmpagliflozinBarbital may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilBarbital may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatBarbital may increase the hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Barbital.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Barbital is combined with Entacapone.Approved, Investigational
EperisoneThe metabolism of Eperisone can be increased when combined with Barbital.Approved, Investigational
EplerenoneBarbital may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolBarbital may increase the hypotensive activities of Epoprostenol.Approved
EprosartanBarbital may increase the hypotensive activities of Eprosartan.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Barbital is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Barbital.Investigational
EsmololBarbital may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Barbital.Approved, Illicit
EstradiolThe therapeutic efficacy of Estradiol can be decreased when used in combination with Barbital.Approved, Investigational, Vet Approved
EstramustineThe therapeutic efficacy of Estramustine can be decreased when used in combination with Barbital.Approved
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Barbital.Approved
Estrone sulfateThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Barbital.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Barbital.Approved
Etacrynic acidBarbital may increase the hypotensive activities of Etacrynic acid.Approved
EthanolBarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Barbital.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Barbital.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Barbital is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Barbital is combined with Ethotoin.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Barbital.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Barbital is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Barbital is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Barbital.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Barbital.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Barbital is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Barbital is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Barbital is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Barbital.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Barbital.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Barbital is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Barbital is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Barbital is combined with Ezogabine.Approved
FelbamateThe serum concentration of Barbital can be increased when it is combined with Felbamate.Approved
FelodipineBarbital may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Barbital.Approved, Illicit, Withdrawn
FendilineThe metabolism of Fendiline can be increased when combined with Barbital.Withdrawn
FenoldopamBarbital may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Barbital.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Barbital is combined with Fexofenadine.Approved
FimasartanBarbital may increase the hypotensive activities of Fimasartan.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Barbital is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Fludiazepam.Approved, Illicit
FluindioneThe metabolism of Fluindione can be increased when combined with Barbital.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Barbital is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Barbital is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Barbital.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Barbital.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Barbital.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Barbital is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Barbital is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Barbital.Approved, Investigational
FosinoprilBarbital may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Barbital is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Barbital is combined with Fospropofol.Approved, Illicit
FurosemideBarbital may increase the hypotensive activities of Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Barbital.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Barbital is combined with gabapentin enacarbil.Approved
GallopamilThe metabolism of Gallopamil can be increased when combined with Barbital.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Barbital.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Barbital is combined with Gepirone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Barbital.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Barbital.Approved, Illicit
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Barbital.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Barbital is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Barbital.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Barbital.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Barbital.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Barbital.Approved, Illicit
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Barbital.Withdrawn
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Barbital.Approved
HydralazineBarbital may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideBarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneBarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideBarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Barbital.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Barbital is combined with Iloperidone.Approved
IloprostBarbital may increase the hypotensive activities of Iloprost.Approved, Investigational
ImidaprilBarbital may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Barbital.Approved
IndalpineThe risk or severity of adverse effects can be increased when Barbital is combined with Indalpine.Investigational, Withdrawn
IndapamideBarbital may increase the orthostatic hypotensive activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Barbital.Withdrawn
IndoraminBarbital may increase the hypotensive activities of Indoramin.Withdrawn
IrbesartanBarbital may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidBarbital may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Barbital.Approved, Vet Approved
Isosorbide DinitrateBarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateBarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineBarbital may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineBarbital may increase the hypotensive activities of Isradipine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Barbital.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Barbital is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Barbital is combined with Ketobemidone.Approved
LabetalolBarbital may increase the hypotensive activities of Labetalol.Approved
LacidipineThe metabolism of Lacidipine can be increased when combined with Barbital.Approved
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Barbital.Approved, Investigational
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Barbital.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Barbital is combined with Levetiracetam.Approved, Investigational
LevobunololBarbital may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Barbital.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Barbital is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Barbital is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Barbital is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Barbital.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Barbital is combined with Levomilnacipran.Approved
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Barbital.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Barbital.Approved
LevosimendanBarbital may increase the hypotensive activities of Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Barbital.Approved, Vet Approved
LisinoprilBarbital may increase the hypotensive activities of Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Barbital.Approved
LofentanilThe risk or severity of adverse effects can be increased when Barbital is combined with Lofentanil.Illicit
LofexidineBarbital may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoratadineThe risk or severity of adverse effects can be increased when Barbital is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Barbital.Approved
LosartanBarbital may increase the hypotensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Barbital.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Barbital is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Barbital is combined with Lurasidone.Approved
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Barbital.Investigational
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved, Vet Approved
ManidipineThe metabolism of Manidipine can be increased when combined with Barbital.Approved
MannitolBarbital may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Barbital is combined with Maprotiline.Approved
MecamylamineBarbital may increase the hypotensive activities of Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Barbital is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Barbital is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Barbital.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Barbital.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Barbital is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Barbital.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Barbital.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Barbital.Approved
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Barbital.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Barbital is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Barbital.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Barbital.Approved, Illicit
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Barbital.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Barbital is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Barbital is combined with Methaqualone.Illicit, Withdrawn
MethazolamideBarbital may increase the hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Barbital is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Barbital.Approved
MethotrimeprazineBarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Barbital.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Barbital is combined with Methsuximide.Approved
MethyclothiazideBarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaBarbital may increase the hypotensive activities of Methyldopa.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Barbital.Approved
MetipranololBarbital may increase the hypotensive activities of Metipranolol.Approved
MetolazoneBarbital may increase the orthostatic hypotensive activities of Metolazone.Approved
MetoprololBarbital may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineBarbital may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved
MibefradilThe metabolism of Mibefradil can be increased when combined with Barbital.Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Barbital.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Barbital is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved, Investigational
MinoxidilBarbital may increase the hypotensive activities of Minoxidil.Approved
MirtazapineBarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoexiprilBarbital may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Barbital is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Barbital.Approved, Investigational
MoxonidineBarbital may increase the hypotensive activities of Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved, Investigational
NadololBarbital may increase the hypotensive activities of Nadolol.Approved
NaftopidilThe metabolism of Naftopidil can be increased when combined with Barbital.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Barbital.Approved
NebivololBarbital may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Barbital is combined with Nefazodone.Approved, Withdrawn
NesiritideBarbital may increase the hypotensive activities of Nesiritide.Approved, Investigational
NicardipineBarbital may increase the hypotensive activities of Nicardipine.Approved
NifedipineBarbital may increase the hypotensive activities of Nifedipine.Approved
NiguldipineThe metabolism of Niguldipine can be increased when combined with Barbital.Experimental
NiludipineThe metabolism of Niludipine can be increased when combined with Barbital.Experimental
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Barbital.Approved
NimesulideThe metabolism of Nimesulide can be increased when combined with Barbital.Approved, Withdrawn
NimodipineBarbital may increase the hypotensive activities of Nimodipine.Approved
NisoldipineBarbital may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Nitrazepam.Approved
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Barbital.Approved
Nitric OxideBarbital may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinBarbital may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideBarbital may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Barbital is combined with Nitrous oxide.Approved, Vet Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Barbital.Approved
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Barbital.Approved
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Barbital.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Barbital is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Barbital.Approved
ObinutuzumabBarbital may increase the hypotensive activities of Obinutuzumab.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Barbital.Approved, Investigational
OlmesartanBarbital may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Barbital is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Barbital.Approved
OpipramolThe metabolism of Opipramol can be increased when combined with Barbital.Investigational
OpiumThe risk or severity of adverse effects can be increased when Barbital is combined with Opium.Approved, Illicit
OrphenadrineBarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Barbital is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Barbital.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Barbital is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Barbital is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Barbital.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Barbital.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Barbital.Approved, Investigational, Vet Approved
PaclitaxelBarbital may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Barbital.Approved
PapaverineBarbital may increase the hypotensive activities of Papaverine.Approved
ParaldehydeBarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Barbital is combined with Paroxetine.Approved, Investigational
PenbutololBarbital may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Barbital.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Barbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved
PerazineThe risk or severity of adverse effects can be increased when Barbital is combined with Perazine.Investigational
PerhexilineThe metabolism of Perhexiline can be increased when combined with Barbital.Approved
PerindoprilBarbital may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Barbital is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Barbital.Approved
PethidineBarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenelzineBarbital may increase the hypotensive activities of Phenelzine.Approved
PhenindioneThe metabolism of Phenindione can be increased when combined with Barbital.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Barbital.Approved
PhenoxybenzamineBarbital may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Barbital is combined with Phenoxyethanol.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Barbital.Approved
PhentolamineBarbital may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Barbital is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Barbital.Approved
PinaveriumThe metabolism of Pinaverium can be increased when combined with Barbital.Approved
PindololBarbital may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Barbital is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Barbital is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Barbital is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Barbital is combined with Pizotifen.Approved
PolythiazideBarbital may increase the orthostatic hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Barbital is combined with Pomalidomide.Approved
PractololThe serum concentration of Practolol can be decreased when it is combined with Barbital.Approved
PramipexoleBarbital may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Barbital is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Prazepam.Approved, Illicit
PrazosinBarbital may increase the hypotensive activities of Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Barbital.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Barbital is combined with Pregnanolone.Investigational
PrenylamineThe metabolism of Prenylamine can be increased when combined with Barbital.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Barbital.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Barbital.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Barbital.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Barbital.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Barbital.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Barbital is combined with Promethazine.Approved
PropacetamolThe metabolism of Propacetamol can be increased when combined with Barbital.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Barbital.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Barbital.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Barbital is combined with Propoxycaine.Approved
PropranololBarbital may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Barbital.Approved
PSD502The risk or severity of adverse effects can be increased when Barbital is combined with PSD502.Investigational
PyridoxineThe metabolism of Barbital can be increased when combined with Pyridoxine.Approved, Nutraceutical, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Barbital.Approved
QuinaprilBarbital may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneBarbital may increase the orthostatic hypotensive activities of Quinethazone.Approved
RacloprideThe risk or severity of adverse effects can be increased when Barbital is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Barbital is combined with Ramelteon.Approved, Investigational
RamiprilBarbital may increase the hypotensive activities of Ramipril.Approved
RasagilineBarbital may increase the hypotensive activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Barbital.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Barbital.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Barbital.Approved
RifabutinThe metabolism of Barbital can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Barbital can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Barbital can be increased when combined with Rifapentine.Approved
RiociguatBarbital may increase the hypotensive activities of Riociguat.Approved
RisedronateThe metabolism of Risedronate can be increased when combined with Barbital.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Barbital.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Barbital is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Barbital is combined with Romifidine.Vet Approved
RopiniroleBarbital may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Barbital.Approved
RotigotineBarbital may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Barbital.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Barbital is combined with S-Ethylisothiourea.Experimental
SacubitrilBarbital may increase the hypotensive activities of Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Barbital is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Barbital is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Barbital.Approved, Vet Approved
SelegilineBarbital may increase the hypotensive activities of Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Barbital is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Barbital is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Barbital.Approved, Vet Approved
Sodium NitriteBarbital may increase the hypotensive activities of Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Barbital.Approved
SotalolBarbital may increase the hypotensive activities of Sotalol.Approved
SpironolactoneBarbital may increase the hypotensive activities of Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Barbital is combined with Stiripentol.Approved
StreptokinaseBarbital may increase the hypotensive activities of Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Barbital.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Barbital.Approved
SuvorexantBarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Synthetic Conjugated Estrogens, AThe therapeutic efficacy of Synthetic Conjugated Estrogens, A can be decreased when used in combination with Barbital.Approved
TamsulosinBarbital may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Barbital is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Barbital is combined with Tasimelteon.Approved
TelmisartanBarbital may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Barbital.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Barbital.Approved
TerazosinBarbital may increase the hypotensive activities of Terazosin.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Barbital is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Barbital is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Barbital is combined with Tetrodotoxin.Investigational
ThalidomideBarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Barbital.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Barbital.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Barbital.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Barbital.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Barbital is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Barbital is combined with Tiagabine.Approved
TianeptineThe metabolism of Tianeptine can be increased when combined with Barbital.Approved
TiaprideThe risk or severity of adverse effects can be increased when Barbital is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Barbital is combined with Tiletamine.Vet Approved
TimololBarbital may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Barbital is combined with Tizanidine.Approved
TolazolineBarbital may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Barbital is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Barbital.Approved
TopiramateThe risk or severity of adverse effects can be increased when Barbital is combined with Topiramate.Approved
TorasemideBarbital may increase the hypotensive activities of Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Barbital.Approved, Investigational
TrandolaprilBarbital may increase the hypotensive activities of Trandolapril.Approved
TranilastThe metabolism of Tranilast can be increased when combined with Barbital.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Barbital is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Barbital.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Barbital.Approved, Investigational
TretinoinBarbital may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneBarbital may increase the hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Barbital.Approved
TrichlormethiazideBarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Barbital.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Barbital.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Barbital.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Barbital is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Barbital is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Barbital.Approved
Valproic AcidThe serum concentration of Barbital can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanBarbital may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Barbital is combined with Venlafaxine.Approved
VerapamilBarbital may increase the hypotensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Barbital is combined with Vigabatrin.Approved
VinpocetineThe metabolism of Vinpocetine can be increased when combined with Barbital.Investigational
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Barbital.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Barbital is combined with Vortioxetine.Approved
WarfarinThe metabolism of Warfarin can be increased when combined with Barbital.Approved
XylazineThe risk or severity of adverse effects can be increased when Barbital is combined with Xylazine.Vet Approved
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Barbital.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Barbital.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Barbital is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Barbital is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Barbital.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Zolazepam.Vet Approved
ZolpidemBarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Barbital is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Barbital.Approved
ZotepineThe risk or severity of adverse effects can be increased when Barbital is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Barbital is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05CA04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.955
Blood Brain Barrier+0.9694
Caco-2 permeable-0.6146
P-glycoprotein substrateNon-substrate0.5238
P-glycoprotein inhibitor INon-inhibitor0.7826
P-glycoprotein inhibitor IINon-inhibitor0.9964
Renal organic cation transporterNon-inhibitor0.9395
CYP450 2C9 substrateNon-substrate0.7915
CYP450 2D6 substrateNon-substrate0.9074
CYP450 3A4 substrateNon-substrate0.7823
CYP450 1A2 substrateNon-inhibitor0.896
CYP450 2C9 inhibitorNon-inhibitor0.9436
CYP450 2D6 inhibitorNon-inhibitor0.9586
CYP450 2C19 inhibitorNon-inhibitor0.918
CYP450 3A4 inhibitorNon-inhibitor0.9723
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9847
Ames testAMES toxic0.5531
CarcinogenicityNon-carcinogens0.8532
BiodegradationNot ready biodegradable0.9462
Rat acute toxicity3.5489 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9913
hERG inhibition (predictor II)Non-inhibitor0.9734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point190 °CPhysProp
boiling point250 °C at 2.20E+01 mm HgPhysProp
water solubility7460 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.65HANSCH,C ET AL. (1995)
logS-1.39ADME Research, USCD
pKa8.14 (at 15 °C)KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility3.23 mg/mLALOGPS
logP0.73ALOGPS
logP0.72ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity44.25 m3·mol-1ChemAxon
Polarizability17.59 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.31 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:09 / Updated on August 17, 2016 12:23